Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Stephan Hutter
Two cases of an imatinib-sensitive PRKG2 :: PDGFRA- positive chronic myeloid neoplasm with basophilia
To the Editor The clinical and morphological phenotype of myeloid/lymphoid neoplasms with tyrosine kinase (TK) gene fusions (MLN-TK) is influenced by both the TK and the partner gene [1]. Here, we report on two patients with an initial diagnosis of a chronic myeloid neoplasm with prominent basophilia, absence of eosinophilia and elevated serum tryptase levels in association with myelofibrosis.
MDS without clonal marker: when depth outperforms breadth
Myelodysplastic neoplasms (MDS) are a heterogeneous group of clonal myeloid neoplasms. The interplay of mutations shapes disease phenotype, progression, and response to therapy, highlighting clonal hematopoiesis (CH) as a central feature of MDS biology. However, in around 10–20% of MDS patients no clonal aberrations are found by standard diagnostic workup [1,2,3].
Comprehensive landscape of secondary cytogenetic and molecular genetic events in multiple myeloma patients at diagnosis
Multiple myeloma (MM) accounts for 1–1.8% of all cancers and represents the second most common hematological malignancy [1]. It is an incurable plasma cell (PC) neoplasm characterized by clonal PC accumulation in the bone marrow (BM), with heterogeneous clinical outcomes and a median diagnostic age of 70 years [2]. The 2022 International Consensus Classification (ICC) [3] divides MM into (1) MM with primary recurrent genetic abnormalities and (2) not otherwise specified (NOS) MM.
EU MAR and UK MAR: Where Are We Now?
Executive Summary What’s new: Further changes to the EU Market Abuse Regulation took effect on 5 June 2026, including in relation to the disclosure of inside information in protracted processes such as mergers. Why it matters: While the changes aim to reduce the onerous compliance requirements imposed on EU issuers, they also demonstrate divergence between the UK and EU regimes.
EU MAR and UK MAR: Where Are We Now?
What's new: Further changes to the EU Market Abuse Regulation took effect on 5 June 2026, including in relation to the disclosure of inside information in protracted processes such as mergers. Why it matters: While the changes aim to...
The clinical relevance of sole loss of chromosome Y in myeloid neoplasms
Dear Editor: Loss of chromosome Y (LOY) is one of the most common age-related somatic genomic alterations in men with up to 20% of healthy men over 80 years of age showing LOY by conventional karyotyping [1,2,3,4]. However, it is also a frequent cytogenetic abnormality in myelodysplastic neoplasms (MDS) [5, 6]. Ouseph et al.
Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia
Introduction Genetic predisposition to chronic myeloid leukemia (CML) is not extensively defined, since CML predominantly affects older adults and leukemogenesis is facilitated by age-related accumulation of secondary mutations. Pediatric cases are rare, but studies show that 10% of pediatric patients with CML carry pathogenic germline variants [1], similar to that observed in myelodysplastic syndrome [2].
Genetic characterization of AML defined by differentiation shows a high frequency of DDX41 mutations
Sandra Huber, Christoph Kornauth—Joint first authors. Huber, S., Kornauth, C., Hutter, S., Meggendorfer, M., Summerer, I., Kern, W., Haferlach, T., Pohlkamp, C. and Hoermann, G. (2026), Genetic characterization of AML defined by differentiation shows a high frequency of DDX41 mutations. Br J Haematol. https://doi.org/10.1111/bjh.70484 DATA AVAILABILITY STATEMENT The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing - Leukemia
|
Abstract In the rapidly evolving field of hematology, the diagnosis of leukemias and lymphomas poses major challenges, despite significant genetic advancements. Although established diagnostic methods comprise a multidisciplinary approach and are considered gold standard, in some cases they fall short in conclusively identifying hematological neoplasms.
By Manja Meggendorfer, Wencke Walter, Stephan Hutter, Uwe M. Martens, Wolfgang Kern, Andreas Hochhaus Verified
|
Nature
Verified
Two ways to complex karyotype in MDS—the role of del(5q) and TP53 - Blood Cancer Journal
Dear Editor, Myelodysplastic neoplasms (MDS) are defined as clonal hematopoietic stem cell neoplasms characterized by cytopenias and morphological dysplasia, and ineffective hematopoiesis with an increased risk of leukemic transformation [1]. In addition, MDS are very heterogeneous with respect to their underlying genetic landscape encompassing also cytogenetic abnormalities [2].
Relevance of blast counts for genetic subclassification in MDS - Leukemia
To the Editor: We read the paper by Al Amri et al. on the independent prognostic significance of blast count in a large cohort of patients with myelodysplastic neoplasms (MDS) with great interest [1].
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase - Leukemia
Abstract Myeloproliferative neoplasms (MPN) are a heterogeneous group of clonal disorders characterized by aberrant hematopoietic proliferation and an intrinsic risk of progression to blast phase. The WHO classification 2022 identifies chronic myeloid leukemia and the BCR::ABL1 negative MPNs polycythemia vera, primary myelofibrosis and essential thrombocythemia as individual entities.
Parallel genomic analysis from paired bone marrow and peripheral blood samples of 200 cytopenic patients - Leukemia
To the Editor: Bone marrow (BM) analysis is required for morphological and genetic assessment in patients evaluated for myelodysplastic neoplasms (MDS) and thus currently represents the gold standard in patients with unexplainable cytopenia [1, 2].
Genomic landscape of CCUS compared to MDS and its implications on risk prediction - Leukemia
To the Editor: The 5th edition of the WHO classification (WHO HAEM5) newly included myeloid precursor lesions introducing clonal cytopenia of undetermined significance (CCUS) as an entity [1]. CCUS is defined as clonal hematopoiesis (CH) in the presence of unexplained, persistent cytopenia requiring detection of either somatic mutations in certain genes or clonal chromosomal abnormalities. Discriminating CCUS from MDS primarily relies on morphologic bone marrow (BM) dysplasia.
MDS subclassification—do we still have to count blasts? - Leukemia
Since their definition, the classification of myelodysplastic neoplasms (MDS) relied on cytomorphology determining dysplasia, cytopenia, and blast count [1, 2]. The revised 4th edition of the WHO classification (WHO 2017) [3], encompasses only one genetically defined entity (MDS with isolated del(5q)). Since then, next-generation sequencing identified many driver genes in MDS [4,5,6].
SEC adopts T+1 settlement cycle for most securities transactions but permits T+2 for firm commitment offerings
|
On February 15, 2023, the Securities and Exchange Commission (SEC) adopted final rule amendments that will shorten the standard settlement cycle for most broker-dealer securities transactions from two business days after the trade date (T+2) to one business day (T+1). The SEC believes that further shortening the settlement cycle to T+1 will reduce market participants’ exposure to credit, market and liquidity risk arising from unsettled transactions.
By Filipe Areno, Brian V. Breheny, Shu Du, Rajeev P. Duggal, Ryan Dzierniejko, Gregory Fernicola, Raquel Fox, Michelle Gasaway, David Goldschmidt, Michael Hong, Stephan Hutter, Thomas Ivey, Haiping Li, James McDonald, James Mcdonald, Gregg Noel, Michael Schwartz, Jonathan Stone, Kenji Taneda, Danny Tricot, Pranav L. Trivedi, Joseph Vebman, Yuting Wu, Dwight Yoo, Michael J. Zeidel, Andrew Brady, Caroline Kim
|
Lexology
Verified
Risk prediction in MDS: independent validation of the IPSS-M—ready for routine? - Leukemia
Myelodysplastic neoplasms (MDS) are clonal disorders of hematopoietic cells characterized by peripheral cytopenias, morphologic dysplasia, ineffective hematopoiesis and risk of leukemic transformation (LT) [1, 2]. Biology and clinical outcome within MDS are extremely heterogeneous, making individual risk prediction key for management and therapy decision.
Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts - Leukemia
To the Editor: Two new proposals for the classification of myeloid malignancies have been presented: the 5th edition of the WHO Classification (WHO 2022 [1]) and the International Consensus Classification (ICC [2]). Here we address differences in entity defining criteria within myelodysplastic neoplasms (MDS), in particular in MDS with low blasts, and discuss accompanying hurdles.
SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase - Leukemia
To the Editor: In AML SF3B1 mutations are recurrently found, most frequently in AML-MRC [1] and were shown to be highly specific for secondary AML (s-AML) arising post MDS or MDS/MPN [2]. Thus, the presence of SF3B1 mutations is considered as diagnostic criteria for AML-MR according to the 5th edition of the WHO classification (WHO 2022; [3]).
SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis - Leukemia
Abstract Recently, MDS with mutated SF3B1 and blast count <5% was proposed as distinct entity with favorable prognosis by the international working group for the prognosis of MDS (IWG-PM), the 5th edition of the WHO classification and the International Consensus Classification. To further characterize this entity with respect to the genomic landscape, AML transformation rate and clinical outcome, we analyzed 734 MDS patients by whole genome sequencing.
Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms - Leukemia
Abstract Myeloperoxidase (MPO) gene alterations with variable clinical penetrance have been found in hereditary MPO deficiency, but their leukemia association in patients and carriers has not been established. Germline MPO alterations were found to be significantly enriched in myeloid neoplasms: 28 pathogenic/likely pathogenic variants were identified in 100 patients. The most common alterations were c.2031-2 A > C, R569W, M519fs* and Y173C accounting for about half of the cases.
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics | Leukemia
To the Editor: Acute myeloid leukemia (AML) is a genetically complex disease. Many different driver mutations are known to cause development of AML, moreover genetic and genomic features are the most important prognostic factors for overall survival [1]. In addition to cytogenetics, which have been pivotal in AML diagnostics and classification for many years, molecular genetics are becoming more important in everyday diagnostic routine.
SPACs Considering German Targets Face Unique Challenges | JD Supra
Takeaways German technology and mid-cap growth companies may find a combination with a U.S. SPAC appealing, but must prepare to meet public capital market requirements. Arranging adequate PIPE funding is crucial to the success of a de-SPAC combination, and German targets may be able to tap local institutions for support.
SPACs: Reshaping M&A and IPOs for European Companies | JD Supra
Special purpose acquisition companies (SPACs), also referred to as “blank check” companies, have reached record numbers in the United States, with 242 SPACs conducting an initial public offering (IPO) on either NYSE or Nasdaq Stock Market and 52 announcing an initial business combination or “de-SPAC” in 2020, up 320% and 156% respectively over 2019, according to the research firm Deal Point Data.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Stephan
Contact Stephan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack